CSIMarket Company Name, Ticker, Suppliers, else..
 
Kala Bio inc   (NASDAQ: KALA)
 
Price: $0.5567 $0.02 3.476%
Day's High: $0.6098999977111816 Week Perf: 6.44 %
Day's Low: $ 0.53 30 Day Perf: -26.26 %
Volume (M): 524,484 52 Wk High: $ 1,030.00
Volume (M$): $ 0 52 Wk Avg: $62.64
Open: $0.53 52 Wk Low: $0.49



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 3
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 0

Business Description


Kala Bio Inc. is a biopharmaceutical company that specializes in the development of innovative therapies for various eye conditions. The company utilizes a proprietary technology platform called AMPPLIFY to enhance the bioavailability and efficacy of its products. Kala Bio's primary focus is on developing treatments for diseases such as dry eye disease, macular edema, and retinal diseases. Their goal is to improve the lives of patients by providing effective and convenient treatment options for these conditions.


   Company Address: 1167 Massachusetts Avenue Arlington 2476 MA
   Company Phone Number: 996-5252   Stock Exchange / Ticker: NASDAQ KALA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARVN   -5.6%    
DERM   -1.59%    
HROW        1.57% 
NKTR        2.19% 
ONC   -2.13%    
XLO        1.01% 
• View Complete Report
   



Financing Agreement

KALA BIO Secures $125 Million in Private Placement Funding

Published Thu, Jun 27 2024 12:01 PM UTC

KALA BIO Secures $12.5 Million in Private Placement Funding
KALA BIO, Inc. (NASDAQ:KALA), a leading biopharmaceutical company focused on developing therapies for eye diseases, has announced a successful private placement agreement with institutional accredited investors. The company will be selling shares of its common stock and Series H Convertible Non-Redeemable Prefer...
Shares

KALA BIO Enriches Workforce with Inducement Grants Amidst Market Challenges, Prioritizing Long-Term Growth Vision

Published Fri, Jan 19 2024 9:01 PM UTC



ARLINGTON, Mass., Jan. 19, 2024 - KALA BIO, Inc. (Nasdaq:KALA), a leading pharmaceutical company specializing in innovative treatments, issued a press release today disclosing the granting of non-statutory stock options to a new employee as an inducement award. This award falls outside the purview of the Company s Amended and Restated 2017 Equity Incentive Plan, in...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.7
Working Capital Ratio 4.84
Leverage Ratio (MRQ) 0.17
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -70.75 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 97.48 $
Book Value 121.95 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,360,000
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -


  Kala Bio Inc Outlook

On March 29 2024 the Kala Bio Inc provided following guidance

KALA BIO, Inc. announced its financial results for the fourth quarter and full year 2023, as well as provided a corporate update. The company is currently advancing its ongoing Phase 2b CHASE trial of KPI-012 for Posterior Corneal Epithelial Dystrophy (PCED), with topline data expected by the end of 2024. Additionally, KALA BIO is exploring opportunities to expand the use of KPI-012 into additional corneal indications.

As of December 31, 2023, the company's cash resources, combined with proceeds from a private placement in March 2024 and anticipated funding from a California Institute for Regenerative Medicine (CIRM) award, are projected to support operations until the third quarter of 2025.

KA...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.